Aligning with our in vitro observations, SCLC-P tumors treated with AU-24118 exhibited significant degradation of its direct targets (SMARCA2/4 and PBRM1), which ensued in downregulation of POU2F3, POU2F3 coactivators, and downstream target expression (GFI1B) (Fig. 3C). Here, SMARCA2 is linked to small cell lung carcinoma.